1
|
Kovalenko A, Eliseeva SV, Collet G, El Abdellaoui S, Natkunarajah S, Lerondel S, Guénée L, Besnard C, Petoud S. A Dual-Mode Near-Infrared Optical and Photoacoustic Imaging Agent Based on a Low Energy Absorbing Ytterbium Complex. J Am Chem Soc 2024. [PMID: 38701376 DOI: 10.1021/jacs.4c03406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/05/2024]
Abstract
Near-infrared (NIR) luminescence and photoacoustic (PA) imaging have attracted increasing attention for the real-time monitoring of biological samples due to high sensitivity, resolution, and pronounced signal detection depth, respectively. For improved contrast, both techniques require imaging agents possessing high absorption in the red-NIR range. Herein, we took advantage of a ternary complex formed with the anionic ytterbium(III) tetrakis(2-thenoyltrifluoroacetonate) ([Yb(tta)4]-) and the cationic NIR-absorbing chromophore, 1,1'-diethyl-2,2'-dicarbocyanine (Cy+), to evaluate its potential to act as a dual-mode NIR luminescence and PA imaging agent. We demonstrated that, upon excitation with red-NIR light, Cy[Yb(tta)4] encapsulated into polystyrene nanoparticles is able to generate both NIR Yb3+ emission and a PA signal in an imaging experiment performed in a tissue-mimicking phantom.
Collapse
Affiliation(s)
- Anton Kovalenko
- Centre de Biophysique Moléculaire, CNRS UPR4301, Université d'Orléans, rue Charles Sadron, 45071 Orléans Cedex 2, France
| | - Svetlana V Eliseeva
- Centre de Biophysique Moléculaire, CNRS UPR4301, Université d'Orléans, rue Charles Sadron, 45071 Orléans Cedex 2, France
| | - Guillaume Collet
- Centre de Biophysique Moléculaire, CNRS UPR4301, Université d'Orléans, rue Charles Sadron, 45071 Orléans Cedex 2, France
- Le Studium Loire Valley Institute for Advanced Studies, 1 rue Dupanloup, 45000 Orléans, France
| | - Saïda El Abdellaoui
- Centre de Biophysique Moléculaire, CNRS UPR4301, Université d'Orléans, rue Charles Sadron, 45071 Orléans Cedex 2, France
| | - Sharuja Natkunarajah
- TAAM Imagerie in Vivo, CNRS UAR44, 3B rue de la Férollerie, 45071 Orléans Cedex 2, France
| | - Stéphanie Lerondel
- TAAM Imagerie in Vivo, CNRS UAR44, 3B rue de la Férollerie, 45071 Orléans Cedex 2, France
| | - Laure Guénée
- Laboratory of Crystallography, University of Geneva, 24 quai Ernest Ansermet, 1211 Geneva 4, Switzerland
| | - Céline Besnard
- Laboratory of Crystallography, University of Geneva, 24 quai Ernest Ansermet, 1211 Geneva 4, Switzerland
| | - Stéphane Petoud
- Centre de Biophysique Moléculaire, CNRS UPR4301, Université d'Orléans, rue Charles Sadron, 45071 Orléans Cedex 2, France
| |
Collapse
|
2
|
Folcher A, Gordienko D, Iamshanova O, Bokhobza A, Shapovalov G, Kannancheri‐Puthooru D, Mariot P, Allart L, Desruelles E, Spriet C, Diez R, Oullier T, Marionneau‐Lambot S, Brisson L, Geraci S, Impheng H, Lehen'kyi V, Haustrate A, Mihalache A, Gosset P, Chadet S, Retif S, Laube M, Sobilo J, Lerondel S, Villari G, Serini G, Pla AF, Roger S, Fromont‐Hankard G, Djamgoz M, Clezardin P, Monteil A, Prevarskaya N. NALCN-mediated sodium influx confers metastatic prostate cancer cell invasiveness. EMBO J 2023; 42:e112198. [PMID: 37278161 PMCID: PMC10308360 DOI: 10.15252/embj.2022112198] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2022] [Revised: 05/09/2023] [Accepted: 05/10/2023] [Indexed: 06/07/2023] Open
Abstract
There is growing evidence that ion channels are critically involved in cancer cell invasiveness and metastasis. However, the molecular mechanisms of ion signaling promoting cancer behavior are poorly understood and the complexity of the underlying remodeling during metastasis remains to be explored. Here, using a variety of in vitro and in vivo techniques, we show that metastatic prostate cancer cells acquire a specific Na+ /Ca2+ signature required for persistent invasion. We identify the Na+ leak channel, NALCN, which is overexpressed in metastatic prostate cancer, as a major initiator and regulator of Ca2+ oscillations required for invadopodia formation. Indeed, NALCN-mediated Na+ influx into cancer cells maintains intracellular Ca2+ oscillations via a specific chain of ion transport proteins including plasmalemmal and mitochondrial Na+ /Ca2+ exchangers, SERCA and store-operated channels. This signaling cascade promotes activity of the NACLN-colocalized proto-oncogene Src kinase, actin remodeling and secretion of proteolytic enzymes, thus increasing cancer cell invasive potential and metastatic lesions in vivo. Overall, our findings provide new insights into an ion signaling pathway specific for metastatic cells where NALCN acts as persistent invasion controller.
Collapse
Affiliation(s)
- Antoine Folcher
- Inserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO LilleUniversity of LilleLilleFrance
| | - Dmitri Gordienko
- Inserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO LilleUniversity of LilleLilleFrance
| | - Oksana Iamshanova
- Inserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO LilleUniversity of LilleLilleFrance
| | - Alexandre Bokhobza
- Inserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO LilleUniversity of LilleLilleFrance
| | - George Shapovalov
- Inserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO LilleUniversity of LilleLilleFrance
| | - Dheeraj Kannancheri‐Puthooru
- Inserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO LilleUniversity of LilleLilleFrance
| | - Pascal Mariot
- Inserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO LilleUniversity of LilleLilleFrance
| | - Laurent Allart
- Inserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO LilleUniversity of LilleLilleFrance
| | - Emilie Desruelles
- Inserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO LilleUniversity of LilleLilleFrance
| | - Corentin Spriet
- TISBio, Unité de Glycobiologie Structurale et Fonctionnelle (UGSF), CNRS, UMR 8576Université de LilleLilleFrance
| | - Raquel Diez
- Cell Physiology Research Group, Department of PhysiologyUniversity of ExtremaduraCáceresSpain
| | | | | | - Lucie Brisson
- Inserm UMR1069, Nutrition Croissance et CancerUniversity of ToursToursFrance
| | - Sandra Geraci
- Univ Lyon, Université Claude Bernard Lyon 1, Inserm UMR 1033 LYOSLyonFrance
| | - Hathaichanok Impheng
- Department of Physiology, Faculty of Medical scienceNaresuan UniversityPhitsanulokThailand
| | - V'yacheslav Lehen'kyi
- Inserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO LilleUniversity of LilleLilleFrance
| | - Aurélien Haustrate
- Inserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO LilleUniversity of LilleLilleFrance
| | - Adriana Mihalache
- Service d'Anatomie et de Cytologie PathologiquesGroupement des Hôpitaux de l'Université Catholique de LilleLilleFrance
| | - Pierre Gosset
- Service d'Anatomie et de Cytologie PathologiquesGroupement des Hôpitaux de l'Université Catholique de LilleLilleFrance
| | - Stéphanie Chadet
- EA4245 Transplantation, Immunology, InflammationUniversity of ToursToursFrance
| | - Stéphanie Retif
- PHENOMIN‐TAAM, CNRS UPS44, Centre d'Imagerie du Petit Animal (CIPA), 3B rue de la FérollerieOrléansFrance
| | - Maryline Laube
- PHENOMIN‐TAAM, CNRS UPS44, Centre d'Imagerie du Petit Animal (CIPA), 3B rue de la FérollerieOrléansFrance
| | - Julien Sobilo
- PHENOMIN‐TAAM, CNRS UPS44, Centre d'Imagerie du Petit Animal (CIPA), 3B rue de la FérollerieOrléansFrance
| | - Stéphanie Lerondel
- PHENOMIN‐TAAM, CNRS UPS44, Centre d'Imagerie du Petit Animal (CIPA), 3B rue de la FérollerieOrléansFrance
| | - Giulia Villari
- Department of OncologyUniversity of Torino School of MedicineCandioloItaly
- Candiolo Cancer Institute – Fondazione del Piemonte per l'Oncologia (FPO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)CandioloItaly
| | - Guido Serini
- Department of OncologyUniversity of Torino School of MedicineCandioloItaly
- Candiolo Cancer Institute – Fondazione del Piemonte per l'Oncologia (FPO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)CandioloItaly
| | | | - Sébastien Roger
- EA4245 Transplantation, Immunology, InflammationUniversity of ToursToursFrance
| | - Gaelle Fromont‐Hankard
- Inserm UMR1069, Nutrition Croissance et CancerUniversity of ToursToursFrance
- Department of PathologyCHRU de ToursToursFrance
| | - Mustafa Djamgoz
- Department of Life SciencesImperial College LondonLondonUK
- Biotechnology Research CentreCyprus International UniversityMersinTürkiye
| | - Philippe Clezardin
- Univ Lyon, Université Claude Bernard Lyon 1, Inserm UMR 1033 LYOSLyonFrance
| | - Arnaud Monteil
- LabEx “Ion Channel Science and Therapeutics”, IGF, CNRS, INSERMUniversity of MontpellierMontpellierFrance
| | - Natalia Prevarskaya
- Inserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO LilleUniversity of LilleLilleFrance
| |
Collapse
|
3
|
Lacerda S, Zhang W, T. M. de Rosales R, Da Silva I, Sobilo J, Lerondel S, Tóth É, Djanashvili K. On the Versatility of Nanozeolite Linde Type L for Biomedical Applications: Zirconium-89 Radiolabeling and In Vivo Positron Emission Tomography Study. ACS Appl Mater Interfaces 2022; 14:32788-32798. [PMID: 35830285 PMCID: PMC9335405 DOI: 10.1021/acsami.2c03841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 03/02/2022] [Accepted: 07/01/2022] [Indexed: 06/15/2023]
Abstract
Porous materials, such as zeolites, have great potential for biomedical applications, thanks to their ability to accommodate positively charged metal-ions and their facile surface functionalization. Although the latter aspect is important to endow the nanoparticles with chemical/colloidal stability and desired biological properties, the possibility for simple ion-exchange enables easy switching between imaging modalities and/or combination with therapy, depending on the envisioned application. In this study, the nanozeolite Linde type L (LTL) with already confirmed magnetic resonance imaging properties, generated by the paramagnetic gadolinium (GdIII) in the inner cavities, was successfully radiolabeled with a positron emission tomography (PET)-tracer zirconium-89 (89Zr). Thereby, exploiting 89Zr-chloride resulted in a slightly higher radiolabeling in the inner cavities compared to the commonly used 89Zr-oxalate, which apparently remained on the surface of LTL. Intravenous injection of PEGylated 89Zr/GdIII-LTL in healthy mice allowed for PET-computed tomography evaluation, revealing initial lung uptake followed by gradual migration of LTL to the liver and spleen. Ex vivo biodistribution confirmed the in vivo stability and integrity of the proposed multimodal probe by demonstrating the original metal/Si ratio being preserved in the organs. These findings reveal beneficial biological behavior of the nanozeolite LTL and hence open the door for follow-up theranostic studies by exploiting the immense variety of metal-based radioisotopes.
Collapse
Affiliation(s)
- Sara Lacerda
- Centre
de Biophysique Moléculaire, CNRS UPR4301, Rue Charles Sadron, Orléans 45071 Cedex 2, France
| | - Wuyuan Zhang
- Department
of Biotechnology, Delft University of Technology, Van der Maasweg 9, Delft 2629 HZ, The Netherlands
| | - Rafael T. M. de Rosales
- School
of Biomedical Engineering & Imaging Sciences, St Thomas’
Hospital, King’s College London, London SE1 7EH, U.K.
| | - Isidro Da Silva
- CEMHTI,
CNRS UPR3079, Université d’Orléans, Orléans 45071, France
| | - Julien Sobilo
- Centre
d’Imagerie du petit Animal, PHENOMIN-TAAM, CNRS UAR44, Orléans F-45071, France
| | - Stéphanie Lerondel
- Centre
d’Imagerie du petit Animal, PHENOMIN-TAAM, CNRS UAR44, Orléans F-45071, France
| | - Éva Tóth
- Centre
de Biophysique Moléculaire, CNRS UPR4301, Rue Charles Sadron, Orléans 45071 Cedex 2, France
| | - Kristina Djanashvili
- Centre
de Biophysique Moléculaire, CNRS UPR4301, Rue Charles Sadron, Orléans 45071 Cedex 2, France
- Department
of Biotechnology, Delft University of Technology, Van der Maasweg 9, Delft 2629 HZ, The Netherlands
- Le Studium,
Loire Valley Institute for Advanced Studies, 1 Rue Dupanloup, Orléans 45000, France
| |
Collapse
|
4
|
Grolez GP, Chinigò G, Barras A, Hammadi M, Noyer L, Kondratska K, Bulk E, Oullier T, Marionneau-Lambot S, Le Mée M, Rétif S, Lerondel S, Bongiovanni A, Genova T, Roger S, Boukherroub R, Schwab A, Fiorio Pla A, Gkika D. TRPM8 as an Anti-Tumoral Target in Prostate Cancer Growth and Metastasis Dissemination. Int J Mol Sci 2022; 23:ijms23126672. [PMID: 35743115 PMCID: PMC9224463 DOI: 10.3390/ijms23126672] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2022] [Revised: 06/05/2022] [Accepted: 06/12/2022] [Indexed: 02/04/2023] Open
Abstract
In the fight against prostate cancer (PCa), TRPM8 is one of the most promising clinical targets. Indeed, several studies have highlighted that TRPM8 involvement is key in PCa progression because of its impact on cell proliferation, viability, and migration. However, data from the literature are somewhat contradictory regarding the precise role of TRPM8 in prostatic carcinogenesis and are mostly based on in vitro studies. The purpose of this study was to clarify the role played by TRPM8 in PCa progression. We used a prostate orthotopic xenograft mouse model to show that TRPM8 overexpression dramatically limited tumor growth and metastasis dissemination in vivo. Mechanistically, our in vitro data revealed that TRPM8 inhibited tumor growth by affecting the cell proliferation and clonogenic properties of PCa cells. Moreover, TRPM8 impacted metastatic dissemination mainly by impairing cytoskeleton dynamics and focal adhesion formation through the inhibition of the Cdc42, Rac1, ERK, and FAK pathways. Lastly, we proved the in vivo efficiency of a new tool based on lipid nanocapsules containing WS12 in limiting the TRPM8-positive cells' dissemination at metastatic sites. Our work strongly supports the protective role of TRPM8 on PCa progression, providing new insights into the potential application of TRPM8 as a therapeutic target in PCa treatment.
Collapse
Affiliation(s)
- Guillaume P. Grolez
- Laboratoire de Physiologie Cellulaire, INSERM U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, University of Lille, 59000 Villeneuve d’Ascq, France; (G.P.G.); (G.C.); (L.N.); (K.K.); (A.F.P.)
| | - Giorgia Chinigò
- Laboratoire de Physiologie Cellulaire, INSERM U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, University of Lille, 59000 Villeneuve d’Ascq, France; (G.P.G.); (G.C.); (L.N.); (K.K.); (A.F.P.)
- Department of Life Science and Systems Biology, University of Turin, 10123 Turin, Italy;
| | - Alexandre Barras
- CNRS, Centrale Lille, Univ. Lille, Univ. Polytechnique Hauts-de-France, UMR 8520—IEMN, 59000 Lille, France; (A.B.); (M.H.); (R.B.)
| | - Mehdi Hammadi
- CNRS, Centrale Lille, Univ. Lille, Univ. Polytechnique Hauts-de-France, UMR 8520—IEMN, 59000 Lille, France; (A.B.); (M.H.); (R.B.)
| | - Lucile Noyer
- Laboratoire de Physiologie Cellulaire, INSERM U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, University of Lille, 59000 Villeneuve d’Ascq, France; (G.P.G.); (G.C.); (L.N.); (K.K.); (A.F.P.)
| | - Kateryna Kondratska
- Laboratoire de Physiologie Cellulaire, INSERM U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, University of Lille, 59000 Villeneuve d’Ascq, France; (G.P.G.); (G.C.); (L.N.); (K.K.); (A.F.P.)
| | - Etmar Bulk
- Institute of Physiology II, University of Münster, 48149 Münster, Germany; (E.B.); (A.S.)
| | - Thibauld Oullier
- Cancéropôle du Grand Ouest, Plateforme In Vivo, 44000 Nantes, France; (T.O.); (S.M.-L.)
| | | | - Marilyne Le Mée
- CNRS UAR44, PHENOMIN-TAAM, 45071 Orléans, France; (M.L.M.); (S.R.); (S.L.)
| | - Stéphanie Rétif
- CNRS UAR44, PHENOMIN-TAAM, 45071 Orléans, France; (M.L.M.); (S.R.); (S.L.)
| | - Stéphanie Lerondel
- CNRS UAR44, PHENOMIN-TAAM, 45071 Orléans, France; (M.L.M.); (S.R.); (S.L.)
| | - Antonino Bongiovanni
- CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41—UMS 2014—PLBS, University of Lille, 59000 Lille, France;
| | - Tullio Genova
- Department of Life Science and Systems Biology, University of Turin, 10123 Turin, Italy;
- Nanostructured Interfaces and Surfaces Centre of Excellence (NIS), University of Turin, 10123 Turin, Italy
| | - Sébastien Roger
- Transplantation, Immunologie et Inflammation T2I-EA 4245, Université de Tours, 37044 Tours, France;
| | - Rabah Boukherroub
- CNRS, Centrale Lille, Univ. Lille, Univ. Polytechnique Hauts-de-France, UMR 8520—IEMN, 59000 Lille, France; (A.B.); (M.H.); (R.B.)
| | - Albrecht Schwab
- Institute of Physiology II, University of Münster, 48149 Münster, Germany; (E.B.); (A.S.)
| | - Alessandra Fiorio Pla
- Laboratoire de Physiologie Cellulaire, INSERM U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, University of Lille, 59000 Villeneuve d’Ascq, France; (G.P.G.); (G.C.); (L.N.); (K.K.); (A.F.P.)
- Department of Life Science and Systems Biology, University of Turin, 10123 Turin, Italy;
- CNRS UAR44, PHENOMIN-TAAM, 45071 Orléans, France; (M.L.M.); (S.R.); (S.L.)
| | - Dimitra Gkika
- CNRS, INSERM, CHU Lille, Centre Oscar Lambret, UMR 9020-UMR 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, University Lille, 59000 Villeneuve d’Ascq, France
- Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720, USA
- Institut Universitaire de France (IUF), 75231 Paris, France
- Correspondence:
| |
Collapse
|
5
|
Buggisch JR, Göhler D, Sobilo J, Lerondel S, Rezniczek GA, Stintz M, Rudolph A, Tabchouri N, Roger S, Ouaissi M, Giger-Pabst U. Development and technical validation of an ultrasound nebulizer to deliver intraperitoneal pressurized aerosols in a rat colon cancer peritoneal metastases model. BMC Cancer 2022; 22:570. [PMID: 35597921 PMCID: PMC9124413 DOI: 10.1186/s12885-022-09668-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2021] [Accepted: 05/11/2022] [Indexed: 11/15/2022] Open
Abstract
Background/aim To develop and validate a nebulizer device for anti-cancer research on pressurized intraperitoneal aerosol supply in a preclinical peritoneal metastases (PM) rat model. Material and methods For aerosol generation, an ultrasonic nebulizer (USN) was modified. Aerosol analyses were performed ex-vivo by laser diffraction spectrometry (LDS). Intraperitoneal (IP) 99mtechnetium sodium pertechnetate (99mTc) aerosol distribution and deposition were quantified by in-vivo single photon emission computed tomography (SPECT/CT) and compared to liquid IP instillation of equivalent volume/doses of 99mTc with and without capnoperitoneum. PM was induced by IP injection of HCT116-Luc2 human colon cancer cells in immunosuppressed RNU rats. Tumor growth was monitored by bioluminescence imaging (BLI), 18F-FDG positron emission tomography (PET) and tissues examination at necropsy. Results The USN was able to establish a stable and reproducible capnoperitoneum at a pressure of 8 to 10 mmHg. LDS showed that the USN provides a polydisperse and monomodal aerosol with a volume-weighted diameter of 2.6 μm. At a CO2 flow rate of 2 L/min with an IP residence time of 3.9 s, the highest drug deposition efficiency was found to be 15 wt.-%. In comparison to liquid instillation, nebulization showed the most homogeneous IP spatial drug deposition. Compared to BLI, 18F-FDG-PET was more sensitive to detect smaller PM nodules measuring only 1–2 mm in diameter. BLI, 18F-FDG PET and necropsy analyses showed relevant PM in all animals. Conclusions The USN together with the PM rat model are suitable for robust and species-specific preclinical pharmacological studies regarding intraperitoneal delivery of pressurized aerosolized drugs and cancer research.
Collapse
Affiliation(s)
- Jonathan R Buggisch
- University of Münster, Medizinische Fakultät, Münster, Germany.,CNRS UPS44, CIPA, PHENOMIN-TAAM, Orléans, France
| | - Daniel Göhler
- Research Group Mechanical Process Engineering, Institute of Process Engineering and Environmental Technology, Technische Universität Dresden, Dresden, Germany.,Technologie-orientierte Partikel-, Analysen- und Sensortechnik, Topas GmbH, Dresden, Germany
| | | | | | - Günther A Rezniczek
- Department of Obstetrics and Gynecology, Marien Hospital Herne, Ruhr-Universität Bochum, Bochum, Germany
| | - Michael Stintz
- Research Group Mechanical Process Engineering, Institute of Process Engineering and Environmental Technology, Technische Universität Dresden, Dresden, Germany
| | - Andreas Rudolph
- Technologie-orientierte Partikel-, Analysen- und Sensortechnik, Topas GmbH, Dresden, Germany
| | - Nicolas Tabchouri
- Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, University Hospital of Tours, Lille, France
| | - Sébastien Roger
- EA4245 Transplantation, Immunologie, Inflammation, Université de Tours, France.,Institut Universitaire de France, Paris, France
| | - Mehdi Ouaissi
- Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, University Hospital of Tours, Lille, France.,EA4245 Transplantation, Immunologie, Inflammation, Université de Tours, France
| | - Urs Giger-Pabst
- EA4245 Transplantation, Immunologie, Inflammation, Université de Tours, France. .,University of Applied Science Düsseldorf, 40489, Düsseldorf, Germany.
| |
Collapse
|
6
|
Guéguinou M, Ibrahim S, Bourgeais J, Robert A, Pathak T, Zhang X, Crottès D, Dupuy J, Ternant D, Monbet V, Guibon R, Flores-Romero H, Lefèvre A, Lerondel S, Le Pape A, Dumas JF, Frank PG, Girault A, Chautard R, Guéraud F, García-Sáez AJ, Ouaissi M, Emond P, Sire O, Hérault O, Fromont-Hankard G, Vandier C, Tougeron D, Trebak M, Raoul W, Lecomte T. Curcumin and NCLX inhibitors share anti-tumoral mechanisms in microsatellite-instability-driven colorectal cancer. Cell Mol Life Sci 2022; 79:284. [PMID: 35526196 DOI: 10.1007/s00018-022-04311-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 04/05/2022] [Accepted: 04/15/2022] [Indexed: 11/03/2022]
Abstract
BACKGROUND AND AIMS Recent evidences highlight a role of the mitochondria calcium homeostasis in the development of colorectal cancer (CRC). To overcome treatment resistance, we aimed to evaluate the role of the mitochondrial sodium-calcium-lithium exchanger (NCLX) and its targeting in CRC. We also identified curcumin as a new inhibitor of NCLX. METHODS We examined whether curcumin and pharmacological compounds induced the inhibition of NCLX-mediated mitochondrial calcium (mtCa2+) extrusion, the role of redox metabolism in this process. We evaluated their anti-tumorigenic activity in vitro and in a xenograft mouse model. We analyzed NCLX expression and associations with survival in The Cancer Genome Atlas (TCGA) dataset and in tissue microarrays from 381 patients with microsatellite instability (MSI)-driven CRC. RESULTS In vitro, curcumin exerted strong anti-tumoral activity through its action on NCLX with mtCa2+ and reactive oxygen species overload associated with a mitochondrial membrane depolarization, leading to reduced ATP production and apoptosis. NCLX inhibition with pharmacological and molecular approaches reproduced the effects of curcumin. NCLX inhibitors decreased CRC tumor growth in vivo. Both transcriptomic analysis of TCGA dataset and immunohistochemical analysis of tissue microarrays demonstrated that higher NCLX expression was associated with MSI status, and for the first time, NCLX expression was significantly associated with recurrence-free survival. CONCLUSIONS Our findings highlight a novel anti-tumoral mechanism of curcumin through its action on NCLX and mitochondria calcium overload that could benefit for therapeutic schedule of patients with MSI CRC.
Collapse
Affiliation(s)
- Maxime Guéguinou
- EA 7501 GICC, Université de Tours, Tours, France.
- N2C, Nutrition Growth and Cancer, Faculté de Médecine, Université de Tours, Inserm, UMR 1069, Tours, France.
| | | | | | - Alison Robert
- N2C, Nutrition Growth and Cancer, Faculté de Médecine, Université de Tours, Inserm, UMR 1069, Tours, France
| | - Trayambak Pathak
- Department of Cellular and Molecular Physiology, College of Medicine, The Pennsylvania State University, 500 University Dr, Hershey, PA, 17033, USA
| | - Xuexin Zhang
- Department of Cellular and Molecular Physiology, College of Medicine, The Pennsylvania State University, 500 University Dr, Hershey, PA, 17033, USA
| | - David Crottès
- N2C, Nutrition Growth and Cancer, Faculté de Médecine, Université de Tours, Inserm, UMR 1069, Tours, France
| | - Jacques Dupuy
- TOXALIM (Research Centre in Food Toxicology)-Team E9-PPCA, Université de Toulouse, UMR 1331 INRAE, ENVT, INP-Purpan, UPS, Toulouse, France
| | - David Ternant
- EA 7501 GICC, Université de Tours, Tours, France
- EA4245 Transplant Immunology and Inflammation, Université de Tours, 10 Boulevard Tonnellé, 37032, Tours, France
| | - Valérie Monbet
- IRMAR Mathematics Research Institute of Rennes, UMR-CNRS 6625, Rennes, France
| | - Roseline Guibon
- N2C, Nutrition Growth and Cancer, Faculté de Médecine, Université de Tours, Inserm, UMR 1069, Tours, France
| | - Hector Flores-Romero
- Institute for Genetics, University of Cologne, Cologne, Germany
- Cologne Excellence Cluster On Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany
- Interfaculty Institute of Biochemistry, Eberhard-Karls-Universität Tübingen, Tübingen, Germany
| | - Antoine Lefèvre
- UMR 1253, iBrain, Université de Tours, Inserm, 37000, Tours, France
| | | | | | - Jean-François Dumas
- N2C, Nutrition Growth and Cancer, Faculté de Médecine, Université de Tours, Inserm, UMR 1069, Tours, France
| | - Philippe G Frank
- N2C, Nutrition Growth and Cancer, Faculté de Médecine, Université de Tours, Inserm, UMR 1069, Tours, France
| | - Alban Girault
- Laboratory of Cellular and Molecular Physiology, UR UPJV 4667, University of Picardie Jules Verne, Amiens, France
| | | | - Françoise Guéraud
- TOXALIM (Research Centre in Food Toxicology)-Team E9-PPCA, Université de Toulouse, UMR 1331 INRAE, ENVT, INP-Purpan, UPS, Toulouse, France
| | - Ana J García-Sáez
- Institute for Genetics, University of Cologne, Cologne, Germany
- Cologne Excellence Cluster On Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany
- Interfaculty Institute of Biochemistry, Eberhard-Karls-Universität Tübingen, Tübingen, Germany
| | - Mehdi Ouaissi
- EA4245 Transplant Immunology and Inflammation, Université de Tours, 10 Boulevard Tonnellé, 37032, Tours, France
| | - Patrick Emond
- UMR 1253, iBrain, Université de Tours, Inserm, 37000, Tours, France
| | - Olivier Sire
- IRDL Institut de Recherche Dupuy de Lôme, UMR-CNRS, 06027, Vannes, France
| | | | - Gaëlle Fromont-Hankard
- N2C, Nutrition Growth and Cancer, Faculté de Médecine, Université de Tours, Inserm, UMR 1069, Tours, France
| | - Christophe Vandier
- N2C, Nutrition Growth and Cancer, Faculté de Médecine, Université de Tours, Inserm, UMR 1069, Tours, France
| | - David Tougeron
- Hepato-Gastroenterology Department, Poitiers University Hospital and Faculty of Medicine of Poitiers, 86000, Poitiers, France
| | - Mohamed Trebak
- Department of Cellular and Molecular Physiology, College of Medicine, The Pennsylvania State University, 500 University Dr, Hershey, PA, 17033, USA
| | - William Raoul
- EA 7501 GICC, Université de Tours, Tours, France
- N2C, Nutrition Growth and Cancer, Faculté de Médecine, Université de Tours, Inserm, UMR 1069, Tours, France
| | - Thierry Lecomte
- EA 7501 GICC, Université de Tours, Tours, France.
- N2C, Nutrition Growth and Cancer, Faculté de Médecine, Université de Tours, Inserm, UMR 1069, Tours, France.
- Department of Hepato-Gastroenterology and Digestive Oncology, CHRU de Tours, Tours, France.
| |
Collapse
|
7
|
Chadet S, Allard J, Brisson L, Lopez-Charcas O, Lemoine R, Heraud A, Lerondel S, Guibon R, Fromont G, Le Pape A, Angoulvant D, Jiang LH, Murrell-Lagnado R, Roger S. P2x4 receptor promotes mammary cancer progression by sustaining autophagy and associated mesenchymal transition. Oncogene 2022; 41:2920-2931. [DOI: 10.1038/s41388-022-02297-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2021] [Revised: 03/18/2022] [Accepted: 03/24/2022] [Indexed: 12/22/2022]
|
8
|
Brisson L, Chadet S, Lopez-Charcas O, Jelassi B, Ternant D, Chamouton J, Lerondel S, Le Pape A, Couillin I, Gombault A, Trovero F, Chevalier S, Besson P, Jiang LH, Roger S. P2X7 Receptor Promotes Mouse Mammary Cancer Cell Invasiveness and Tumour Progression, and Is a Target for Anticancer Treatment. Cancers (Basel) 2020; 12:cancers12092342. [PMID: 32825056 PMCID: PMC7565976 DOI: 10.3390/cancers12092342] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2020] [Revised: 08/12/2020] [Accepted: 08/17/2020] [Indexed: 12/20/2022] Open
Abstract
The P2X7 receptor is an ATP-gated cation channel with a still ambiguous role in cancer progression, proposed to be either pro- or anti-cancerous, depending on the cancer or cell type in the tumour. Its role in mammary cancer progression is not yet defined. Here, we show that P2X7 receptor is functional in highly aggressive mammary cancer cells, and induces a change in cell morphology with fast F-actin reorganization and formation of filopodia, and promotes cancer cell invasiveness through both 2- and 3-dimensional extracellular matrices in vitro. Furthermore, P2X7 receptor sustains Cdc42 activity and the acquisition of a mesenchymal phenotype. In an immunocompetent mouse mammary cancer model, we reveal that the expression of P2X7 receptor in cancer cells, but not in the host mice, promotes tumour growth and metastasis development, which were reduced by treatment with specific P2X7 antagonists. Our results demonstrate that P2X7 receptor drives mammary tumour progression and represents a pertinent target for mammary cancer treatment.
Collapse
Affiliation(s)
- Lucie Brisson
- Inserm UMR1069-Nutrition, Growth and Cancer, University of Tours, 37032 Tours, France; (L.B.); (J.C.); (S.C.)
| | - Stéphanie Chadet
- EA4245-Transplantation, Immunology and Inflammation, University of Tours, 37032 Tours, France; (S.C.); (O.L.-C.); (B.J.); (D.T.); (P.B.); (L.-H.J.)
| | - Osbaldo Lopez-Charcas
- EA4245-Transplantation, Immunology and Inflammation, University of Tours, 37032 Tours, France; (S.C.); (O.L.-C.); (B.J.); (D.T.); (P.B.); (L.-H.J.)
| | - Bilel Jelassi
- EA4245-Transplantation, Immunology and Inflammation, University of Tours, 37032 Tours, France; (S.C.); (O.L.-C.); (B.J.); (D.T.); (P.B.); (L.-H.J.)
| | - David Ternant
- EA4245-Transplantation, Immunology and Inflammation, University of Tours, 37032 Tours, France; (S.C.); (O.L.-C.); (B.J.); (D.T.); (P.B.); (L.-H.J.)
| | - Julie Chamouton
- Inserm UMR1069-Nutrition, Growth and Cancer, University of Tours, 37032 Tours, France; (L.B.); (J.C.); (S.C.)
| | - Stéphanie Lerondel
- CNRS UPS44 TAAM, PHENOMIN, Centre d’Imagerie du Petit Animal, 45071 Orléans, France; (S.L.); (A.L.P.)
| | - Alain Le Pape
- CNRS UPS44 TAAM, PHENOMIN, Centre d’Imagerie du Petit Animal, 45071 Orléans, France; (S.L.); (A.L.P.)
| | - Isabelle Couillin
- Laboratory of Molecular and Experimental Immunology and Neurogenetics, UMR 7355, CNRS, University of Orléans, 45071 Orléans, France; (I.C.); (A.G.)
| | - Aurélie Gombault
- Laboratory of Molecular and Experimental Immunology and Neurogenetics, UMR 7355, CNRS, University of Orléans, 45071 Orléans, France; (I.C.); (A.G.)
| | | | - Stéphan Chevalier
- Inserm UMR1069-Nutrition, Growth and Cancer, University of Tours, 37032 Tours, France; (L.B.); (J.C.); (S.C.)
| | - Pierre Besson
- EA4245-Transplantation, Immunology and Inflammation, University of Tours, 37032 Tours, France; (S.C.); (O.L.-C.); (B.J.); (D.T.); (P.B.); (L.-H.J.)
| | - Lin-Hua Jiang
- EA4245-Transplantation, Immunology and Inflammation, University of Tours, 37032 Tours, France; (S.C.); (O.L.-C.); (B.J.); (D.T.); (P.B.); (L.-H.J.)
- School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK
- Sino-UK Joint Laboratory of Brain Function and Injury and Department of Physiology and Pathophysiology, Xinxiang Medical University, Xinxiang 453003, China
| | - Sébastien Roger
- EA4245-Transplantation, Immunology and Inflammation, University of Tours, 37032 Tours, France; (S.C.); (O.L.-C.); (B.J.); (D.T.); (P.B.); (L.-H.J.)
- Institut Universitaire de France, 75005 Paris, France
- Correspondence: ; Tel.: +33-2-47-36-61-30
| |
Collapse
|
9
|
Lutter JC, Eliseeva SV, Collet G, Martinić I, Kampf JW, Schneider BL, Carichner A, Sobilo J, Lerondel S, Petoud S, Pecoraro VL. Iodinated Metallacrowns: Toward Combined Bimodal Near‐Infrared and X‐Ray Contrast Imaging Agents. Chemistry 2020; 26:1274-1277. [DOI: 10.1002/chem.201905241] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2019] [Indexed: 12/21/2022]
Affiliation(s)
- Jacob C. Lutter
- Department of ChemistryWillard H. Dow LaboratoriesThe University of Michigan Ann Arbor MI 48109 United States
| | | | - Guillaume Collet
- Centre de Biophysique MoléculaireCNRS UPR 4301 45071 Orléans Cedex 2 France
| | - Ivana Martinić
- Centre de Biophysique MoléculaireCNRS UPR 4301 45071 Orléans Cedex 2 France
| | - Jeff W. Kampf
- Department of ChemistryWillard H. Dow LaboratoriesThe University of Michigan Ann Arbor MI 48109 United States
| | - Bernadette L. Schneider
- Department of ChemistryWillard H. Dow LaboratoriesThe University of Michigan Ann Arbor MI 48109 United States
| | - Aidan Carichner
- Department of ChemistryWillard H. Dow LaboratoriesThe University of Michigan Ann Arbor MI 48109 United States
| | - Julien Sobilo
- Centre d'Imagerie du Petit AnimalPHENOMIN-TAAM 45071 Orléans Cedex 2 France
| | - Stéphanie Lerondel
- Centre d'Imagerie du Petit AnimalPHENOMIN-TAAM 45071 Orléans Cedex 2 France
| | - Stéphane Petoud
- Centre de Biophysique MoléculaireCNRS UPR 4301 45071 Orléans Cedex 2 France
| | - Vincent L. Pecoraro
- Department of ChemistryWillard H. Dow LaboratoriesThe University of Michigan Ann Arbor MI 48109 United States
| |
Collapse
|
10
|
Giger-Pabst U, Bucur P, Roger S, Falkenstein TA, Tabchouri N, Le Pape A, Lerondel S, Demtröder C, Salamé E, Ouaissi M. Comparison of Tissue and Blood Concentrations of Oxaliplatin Administrated by Different Modalities of Intraperitoneal Chemotherapy. Ann Surg Oncol 2019; 26:4445-4451. [PMID: 31399820 DOI: 10.1245/s10434-019-07695-z] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2019] [Indexed: 01/17/2023]
Abstract
BACKGROUND Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new technology for delivering intraperitoneal chemotherapy. It is generally assumed that with PIPAC, the ratio of peritoneal to systemic drug concentration is superior to liquid hyperthermic intraperitoneal chemotherapy (HIPEC). To date, no direct comparative data are available supporting such an assumption. MATERIALS AND METHODS Twelve 65-day-old pigs were randomly separated into three groups of four pigs each, all of which received intraperitoneal chemotherapy using the following administration methods: PIPAC with oxaliplatin 92 mg in 150 ml dextrose 5% (Group 1); PIPAC with electrostatic aerosol precipitation (ePIPAC; Group 2); or laparoscopic HIPEC (L-HIPEC) with oxaliplatin 400 mg in 4 L dextrose 5% at 42 °C (Group 3). Serial blood and peritoneal tissue concentrations of oxaliplatin were determined by spectrometry. RESULTS In all three groups, the maximum concentration of oxaliplatin in blood was detected 50-60 min after onset of the chemotherapy experiments, with no significant differences among the three groups (p = 0.7994). Blood oxaliplatin concentrations (0-30 min) were significantly higher in the L-HIPEC group compared with the ePIPAC group (p < 0.05). No difference was found for the overall systemic oxaliplatin absorption (area under the curve). Overall concentrations in the peritoneum were not different among the three groups (p = 0.4725), but were significantly higher in the visceral peritoneum in the PIPAC group (p = 0.0242). CONCLUSIONS Blood and tissue concentrations were comparable between all groups; however, depending on the intraperitoneal area examined and the time points of drug delivery, the concentrations differed significantly between the three groups.
Collapse
Affiliation(s)
- Urs Giger-Pabst
- Department of General, Visceral and Transplant Surgery, University of Münster, Münster, Germany.,Department of General Surgery, Marien Hospital Herne, Ruhr University Bochum, Herne, Germany
| | - Petru Bucur
- Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Chambray Les Tours, France
| | - Sébastien Roger
- EA4245 Transplantation Immunologie Inflammation, Université de Tours, Tours, France
| | | | - Nicolas Tabchouri
- Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Chambray Les Tours, France
| | | | | | - Cédric Demtröder
- Department of General, Visceral and Transplant Surgery, University of Münster, Münster, Germany.,Department of General Surgery, Marien Hospital Herne, Ruhr University Bochum, Herne, Germany
| | - Ephrem Salamé
- Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Chambray Les Tours, France
| | - Mehdi Ouaissi
- Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Chambray Les Tours, France. .,EA4245 Transplantation Immunologie Inflammation, Université de Tours, Tours, France.
| |
Collapse
|
11
|
Benabdallah N, Sai-Maurel C, Franck D, de Labriolle-Vaylet C, Desbrée A, Cherel M, Gouard S, Bertho JM, Kereselidze D, Donnard J, Lerondel S, Chauchereau A, Chouin N, Bernardini M. Optimization of Dosimetry in Alpha Therapy: Microlocalisation of 223Ra in Mouse Models of Metastasis from Prostate Cancer and Renal Cell Carcinoma. J Med Imaging Radiat Sci 2019. [DOI: 10.1016/j.jmir.2019.03.033] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
12
|
Garrido MF, Martin NJP, Bertrand M, Gaudin C, Commo F, El Kalaany N, Al Nakouzi N, Fazli L, Del Nery E, Camonis J, Perez F, Lerondel S, Le Pape A, Compagno D, Gleave M, Loriot Y, Désaubry L, Vagner S, Fizazi K, Chauchereau A. Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer. Clin Cancer Res 2018; 25:710-723. [PMID: 30322877 DOI: 10.1158/1078-0432.ccr-18-0704] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2018] [Revised: 07/29/2018] [Accepted: 10/10/2018] [Indexed: 11/16/2022]
Abstract
PURPOSE Targeted therapies that use the signaling pathways involved in prostate cancer are required to overcome chemoresistance and improve treatment outcomes for men. Molecular chaperones play a key role in the regulation of protein homeostasis and are potential targets for overcoming chemoresistance.Experimental Design: We established 4 chemoresistant prostate cancer cell lines and used image-based high-content siRNA functional screening, based on gene-expression signature, to explore mechanisms of chemoresistance and identify new potential targets with potential roles in taxane resistance. The functional role of a new target was assessed by in vitro and in vivo silencing, and mass spectrometry analysis was used to identify its downstream effectors. RESULTS We identified FKBP7, a prolyl-peptidyl isomerase overexpressed in docetaxel-resistant and in cabazitaxel-resistant prostate cancer cells. This is the first study to characterize the function of human FKBP7 and explore its role in cancer. We discovered that FKBP7 was upregulated in human prostate cancers and its expression correlated with the recurrence observed in patients receiving docetaxel. FKBP7 silencing showed that FKBP7 is required to maintain the growth of chemoresistant cell lines and chemoresistant tumors in mice. Mass spectrometry analysis revealed that FKBP7 interacts with eIF4G, a component of the eIF4F translation initiation complex, to mediate the survival of chemoresistant cells. Using small-molecule inhibitors of eIF4A, the RNA helicase component of eIF4F, we were able to kill docetaxel- and cabazitaxel-resistant cells. CONCLUSIONS Targeting FKBP7 or the eIF4G-containing eIF4F translation initiation complex could be novel therapeutic strategies to eradicate taxane-resistant prostate cancer cells.
Collapse
Affiliation(s)
- Marine F Garrido
- Prostate Cancer Group, INSERM UMR981, Villejuif, France.,Univ Paris-Sud, UMR981, Villejuif, France.,Gustave Roussy, Villejuif, France
| | - Nicolas J-P Martin
- Prostate Cancer Group, INSERM UMR981, Villejuif, France.,Univ Paris-Sud, UMR981, Villejuif, France.,Gustave Roussy, Villejuif, France
| | - Matthieu Bertrand
- Prostate Cancer Group, INSERM UMR981, Villejuif, France.,Univ Paris-Sud, UMR981, Villejuif, France.,Gustave Roussy, Villejuif, France
| | - Catherine Gaudin
- Prostate Cancer Group, INSERM UMR981, Villejuif, France.,Univ Paris-Sud, UMR981, Villejuif, France.,Gustave Roussy, Villejuif, France
| | - Frédéric Commo
- Prostate Cancer Group, INSERM UMR981, Villejuif, France.,Univ Paris-Sud, UMR981, Villejuif, France.,Gustave Roussy, Villejuif, France
| | - Nassif El Kalaany
- Prostate Cancer Group, INSERM UMR981, Villejuif, France.,Univ Paris-Sud, UMR981, Villejuif, France.,Gustave Roussy, Villejuif, France
| | - Nader Al Nakouzi
- Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| | - Ladan Fazli
- Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| | - Elaine Del Nery
- Institut Curie, PSL Research University, Paris, France.,Biophenics High-Content Screening Laboratory, Cell and Tissue Imaging Facility (PICT-IBiSA), Paris, France
| | - Jacques Camonis
- Institut Curie, PSL Research University, Paris, France.,Biophenics High-Content Screening Laboratory, Cell and Tissue Imaging Facility (PICT-IBiSA), Paris, France.,INSERM, U830, Paris, France
| | - Franck Perez
- Institut Curie, PSL Research University, Paris, France.,Biophenics High-Content Screening Laboratory, Cell and Tissue Imaging Facility (PICT-IBiSA), Paris, France.,CNRS, UMR144, Paris, France
| | | | | | - Daniel Compagno
- Molecular and Functional Glyco-Oncology Lab, IQUIBICEN-CONICET, Facultad de Ciencias Exactas y Naturales-Universidad de Buenos Aires, CABA, Argentina
| | - Martin Gleave
- Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| | - Yohann Loriot
- Prostate Cancer Group, INSERM UMR981, Villejuif, France.,Univ Paris-Sud, UMR981, Villejuif, France.,Gustave Roussy, Villejuif, France
| | | | - Stéphan Vagner
- Institut Curie, PSL Research University, Paris, France.,CNRS, UMR3348, Orsay, France
| | - Karim Fizazi
- Prostate Cancer Group, INSERM UMR981, Villejuif, France.,Univ Paris-Sud, UMR981, Villejuif, France.,Gustave Roussy, Villejuif, France
| | - Anne Chauchereau
- Prostate Cancer Group, INSERM UMR981, Villejuif, France. .,Univ Paris-Sud, UMR981, Villejuif, France.,Gustave Roussy, Villejuif, France
| |
Collapse
|
13
|
Malikidogo KP, Da Silva I, Morfin JF, Lacerda S, Barantin L, Sauvage T, Sobilo J, Lerondel S, Tóth É, Bonnet CS. A cocktail of 165Er(iii) and Gd(iii) complexes for quantitative detection of zinc using SPECT and MRI. Chem Commun (Camb) 2018; 54:7597-7600. [DOI: 10.1039/c8cc03407a] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Quantitative zinc determination by nuclear and MR imaging using two Ln3+ complexes, including purified 165Er3+, indispensable for metal ion quantification.
Collapse
Affiliation(s)
- Kyangwi P. Malikidogo
- Centre de Biophysique Moléculaire
- CNRS UPR 4301
- Université d’Orléans
- Rue Charles Sadron
- F-45071 Orléans 2
| | - Isidro Da Silva
- CEMHTI
- CNRS UPR3079
- Université d’Orléans
- F-45071 Orléans 2
- France
| | - Jean-François Morfin
- Centre de Biophysique Moléculaire
- CNRS UPR 4301
- Université d’Orléans
- Rue Charles Sadron
- F-45071 Orléans 2
| | - Sara Lacerda
- Centre de Biophysique Moléculaire
- CNRS UPR 4301
- Université d’Orléans
- Rue Charles Sadron
- F-45071 Orléans 2
| | | | - Thierry Sauvage
- CEMHTI
- CNRS UPR3079
- Université d’Orléans
- F-45071 Orléans 2
- France
| | - Julien Sobilo
- Centre d’Imagerie du petit Animal
- PHENOMIN-TAAM
- CNRS UPS44
- F-45071 Orléans 2
- France
| | - Stéphanie Lerondel
- Centre d’Imagerie du petit Animal
- PHENOMIN-TAAM
- CNRS UPS44
- F-45071 Orléans 2
- France
| | - Éva Tóth
- Centre de Biophysique Moléculaire
- CNRS UPR 4301
- Université d’Orléans
- Rue Charles Sadron
- F-45071 Orléans 2
| | - Célia S. Bonnet
- Centre de Biophysique Moléculaire
- CNRS UPR 4301
- Université d’Orléans
- Rue Charles Sadron
- F-45071 Orléans 2
| |
Collapse
|
14
|
Renoux B, Raes F, Legigan T, Péraudeau E, Eddhif B, Poinot P, Tranoy-Opalinski I, Alsarraf J, Koniev O, Kolodych S, Lerondel S, Le Pape A, Clarhaut J, Papot S. Targeting the tumour microenvironment with an enzyme-responsive drug delivery system for the efficient therapy of breast and pancreatic cancers. Chem Sci 2017; 8:3427-3433. [PMID: 28507714 PMCID: PMC5417048 DOI: 10.1039/c7sc00472a] [Citation(s) in RCA: 75] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2017] [Accepted: 03/01/2017] [Indexed: 12/21/2022] Open
Abstract
The development of novel therapeutic strategies allowing the destruction of tumour cells while sparing healthy tissues is one of the main challenges of cancer chemotherapy. Here, we report on the design and antitumour activity of a low-molecular-weight drug delivery system programmed for the selective release of the potent monomethylauristatin E in the tumour microenvironment of solid tumours. After intravenous administration, this compound binds covalently to plasmatic albumin through Michael addition, thereby enabling its passive accumulation in tumours where extracellular β-glucuronidase initiates the selective release of the drug. This targeting device produces outstanding therapeutic efficacy on orthotopic triple-negative mammary and pancreatic tumours in mice (50% and 33% of mice with the respective tumours cured), leading to impressive reduction or even disappearance of tumours without inducing side effects.
Collapse
Affiliation(s)
- Brigitte Renoux
- Institut de Chimie des Milieux et des Matériaux de Poitiers (IC2MP) , Université de Poitiers , CNRS , Groupe "Systèmes Moléculaires Programmés" , 4 rue Michel Brunet, TSA 51106 , F-86073 Poitiers , France .
| | - Florian Raes
- UPS no. 44 PHENOMIN TAAM-CIPA , CNRS , 3B rue de la Férollerie , F-45071 Orléans , France
| | - Thibaut Legigan
- Institut de Chimie des Milieux et des Matériaux de Poitiers (IC2MP) , Université de Poitiers , CNRS , Groupe "Systèmes Moléculaires Programmés" , 4 rue Michel Brunet, TSA 51106 , F-86073 Poitiers , France .
| | - Elodie Péraudeau
- Université de Poitiers , CNRS , ERL 7368, 1 rue Georges Bonnet, TSA 51106 , F-86073 Poitiers , France
- CHU de Poitiers , 2 rue de la Miléterie, CS 90577 , F-86021 Poitiers , France
| | - Balkis Eddhif
- Institut de Chimie des Milieux et des Matériaux de Poitiers (IC2MP) , Université de Poitiers , CNRS , Equipe Eau, Géochimie Organique, Santé (EGS), 4 rue Michel Brunet, TSA 51106 , F-86073 Poitiers , France
| | - Pauline Poinot
- Institut de Chimie des Milieux et des Matériaux de Poitiers (IC2MP) , Université de Poitiers , CNRS , Equipe Eau, Géochimie Organique, Santé (EGS), 4 rue Michel Brunet, TSA 51106 , F-86073 Poitiers , France
| | - Isabelle Tranoy-Opalinski
- Institut de Chimie des Milieux et des Matériaux de Poitiers (IC2MP) , Université de Poitiers , CNRS , Groupe "Systèmes Moléculaires Programmés" , 4 rue Michel Brunet, TSA 51106 , F-86073 Poitiers , France .
| | - Jérôme Alsarraf
- Institut de Chimie des Milieux et des Matériaux de Poitiers (IC2MP) , Université de Poitiers , CNRS , Groupe "Systèmes Moléculaires Programmés" , 4 rue Michel Brunet, TSA 51106 , F-86073 Poitiers , France .
| | - Oleksandr Koniev
- Syndivia SAS , 650 Bd Gonthier d'Andernach , 67400 Illkirch , France
| | - Sergii Kolodych
- Syndivia SAS , 650 Bd Gonthier d'Andernach , 67400 Illkirch , France
| | - Stéphanie Lerondel
- UPS no. 44 PHENOMIN TAAM-CIPA , CNRS , 3B rue de la Férollerie , F-45071 Orléans , France
| | - Alain Le Pape
- UPS no. 44 PHENOMIN TAAM-CIPA , CNRS , 3B rue de la Férollerie , F-45071 Orléans , France
| | - Jonathan Clarhaut
- Institut de Chimie des Milieux et des Matériaux de Poitiers (IC2MP) , Université de Poitiers , CNRS , Groupe "Systèmes Moléculaires Programmés" , 4 rue Michel Brunet, TSA 51106 , F-86073 Poitiers , France .
- CHU de Poitiers , 2 rue de la Miléterie, CS 90577 , F-86021 Poitiers , France
| | - Sébastien Papot
- Institut de Chimie des Milieux et des Matériaux de Poitiers (IC2MP) , Université de Poitiers , CNRS , Groupe "Systèmes Moléculaires Programmés" , 4 rue Michel Brunet, TSA 51106 , F-86073 Poitiers , France .
| |
Collapse
|
15
|
Arthuis CJ, Novell A, Raes F, Escoffre JM, Lerondel S, Le Pape A, Bouakaz A, Perrotin F. Real-Time Monitoring of Placental Oxygenation during Maternal Hypoxia and Hyperoxygenation Using Photoacoustic Imaging. PLoS One 2017; 12:e0169850. [PMID: 28081216 PMCID: PMC5232166 DOI: 10.1371/journal.pone.0169850] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2016] [Accepted: 12/22/2016] [Indexed: 12/15/2022] Open
Abstract
Purpose This preclinical study aimed to evaluate placental oxygenation in pregnant rats by real-time photoacoustic (PA) imaging on different days of gestation and to specify variations in placental oxygen saturation under conditions of maternal hypoxia and hyperoxygenation. Material and methods Placentas of fifteen Sprague-Dawley rats were examined on days 14, 17, and 20 of pregnancy with a PA imaging system coupled to high-resolution ultrasound imaging. Pregnant rats were successively exposed to hyperoxygenated and hypoxic conditions by changing the oxygen concentration in inhaled gas. Tissue oxygen saturation was quantitatively analyzed by real-time PA imaging in the skin and 3 regions of the placenta. All procedures were performed in accordance with applicable ethical guidelines and approved by the animal care committee. Results Maternal hypoxia was associated with significantly greater decrease in blood oxygen saturation (ΔO2 Saturation) in the skin (70.74% ±7.65) than in the mesometrial triangle (32.66% ±5.75) or other placental areas (labyrinth: 18.58% ± 6.61; basal zone: 13.13% ±5.72) on different days of pregnancy (P<0.001). ΔO2 Saturation did not differ significantly between the labyrinth, the basal zone, and the decidua. After the period of hypoxia, maternal hyperoxygenation led to a significant rise in oxygen saturation, which returned to its initial values in the different placental regions (P<0.001). Conclusions PA imaging enables the variation of blood oxygen saturation to be monitored in the placenta during maternal hypoxia or hyperoxygenation. This first preclinical study suggests that the placenta plays an important role in protecting the fetus against maternal hypoxia.
Collapse
Affiliation(s)
- Chloé J. Arthuis
- Inserm U930, François Rabelais University, Tours, France
- University Hospital Center of Tours, Department of Obstetrics, Gynecology and Fetal Medicine, Tours, France
- * E-mail:
| | - Anthony Novell
- Inserm U930, François Rabelais University, Tours, France
| | - Florian Raes
- PHENOMIN-TAAM-UPS44, Center for Small Animal Imaging (CIPA), CNRS Orléans, France
| | | | - Stéphanie Lerondel
- PHENOMIN-TAAM-UPS44, Center for Small Animal Imaging (CIPA), CNRS Orléans, France
| | - Alain Le Pape
- PHENOMIN-TAAM-UPS44, Center for Small Animal Imaging (CIPA), CNRS Orléans, France
| | - Ayache Bouakaz
- Inserm U930, François Rabelais University, Tours, France
| | - Franck Perrotin
- Inserm U930, François Rabelais University, Tours, France
- University Hospital Center of Tours, Department of Obstetrics, Gynecology and Fetal Medicine, Tours, France
| |
Collapse
|
16
|
Desoubeaux G, Reichert JM, Sleeman M, Reckamp KL, Ryffel B, Adamczewski JP, Sweeney TD, Vanbever R, Diot P, Owen CA, Page C, Lerondel S, Le Pape A, Heuze-Vourc'h N. Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 - April 1, 2016, Tours, France. MAbs 2016; 8:999-1009. [PMID: 27266390 PMCID: PMC4968091 DOI: 10.1080/19420862.2016.1196521] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Monoclonal antibody (mAb) therapeutics have tremendous potential to benefit patients with lung diseases, for which there remains substantial unmet medical need. To capture the current state of mAb research and development in the area of respiratory diseases, the Research Center of Respiratory Diseases (CEPR-INSERM U1100), the Laboratory of Excellence “MAbImprove,” the GDR 3260 “Antibodies and therapeutic targeting,” and the Grant Research program ARD2020 “Biotherapeutics” invited speakers from industry, academic and government organizations to present their recent research results at the Therapeutic Monoclonal Antibodies for Respiratory Diseases: Current challenges and perspectives congress held March 31 – April 1, 2016 in Tours, France.
Collapse
Affiliation(s)
- Guillaume Desoubeaux
- a Université François-Rabelais , Tours , France.,b INSERM, Center d'Etude des Pathologies Respiratoires , Tours , France.,c Centre Hospitalo-Universitaire de Tours , Tours , France
| | - Janice M Reichert
- d The Antibody Society , Framingham , MA , USA.,e Reichert Biotechnology Consulting LLC , Framingham MA , USA
| | | | - Karen L Reckamp
- g City of Hope, Comprehensive Cancer Center , Duarte , CA , USA
| | - Bernhard Ryffel
- h Université d'Orléans , Orléans , France.,i University of Cape Town, Institute of Infectious Disease and Molecular Medicine (IDM) , Cape Town , South Africa
| | | | | | - Rita Vanbever
- l Université Catholique de Louvain, Louvain Drug Research Institute , Brussels , Belgium
| | - Patrice Diot
- a Université François-Rabelais , Tours , France.,b INSERM, Center d'Etude des Pathologies Respiratoires , Tours , France.,c Centre Hospitalo-Universitaire de Tours , Tours , France
| | - Caroline A Owen
- m Harvard Medical School, Brigham and Women's Hospital , Boston , MA , USA.,n Lovelace Respiratory Research Institute , Albuquerque , NM , USA
| | - Clive Page
- o King's College, Sackler Institute of Pulmonary Pharmacology , London , UK
| | | | - Alain Le Pape
- a Université François-Rabelais , Tours , France.,b INSERM, Center d'Etude des Pathologies Respiratoires , Tours , France.,p PHENOMIN-TAAM CNRS, CIPA , Orléans , France
| | - Nathalie Heuze-Vourc'h
- a Université François-Rabelais , Tours , France.,b INSERM, Center d'Etude des Pathologies Respiratoires , Tours , France
| |
Collapse
|
17
|
Raes F, Sobilo J, Le Mée M, Rétif S, Natkunarajah S, Lerondel S, Le Pape A. High Resolution Ultrasound and Photoacoustic Imaging of Orthotopic Lung Cancer in Mice: New Perspectives for Onco-Pharmacology. PLoS One 2016; 11:e0153532. [PMID: 27070548 PMCID: PMC4829195 DOI: 10.1371/journal.pone.0153532] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2016] [Accepted: 03/30/2016] [Indexed: 11/18/2022] Open
Abstract
Objectives We have developed a relevant preclinical model associated with a specific imaging protocol dedicated to onco-pharmacology studies in mice. Materials and Methods We optimized both the animal model and an ultrasound imaging procedure to follow up longitudinally the lung tumor growth in mice. Moreover we proposed to measure by photoacoustic imaging the intratumoral hypoxia, which is a crucial parameter responsible for resistance to therapies. Finally, we compared ultrasound data to x-ray micro computed tomography and volumetric measurements to validate the relevance of this approach on the NCI-H460 human orthotopic lung tumor. Results This study demonstrates the ability of ultrasound imaging to detect and monitor the in vivo orthotopic lung tumor growth by high resolution ultrasound imaging. This approach enabled us to characterize key biological parameters such as oxygenation, perfusion status and vascularization of tumors. Conclusion Such an experimental approach has never been reported previously and it would provide a nonradiative tool for assessment of anticancer therapeutic efficacy in mice. Considering the absence of ultrasound propagation through the lung parenchyma, this strategy requires the implantation of tumors strictly located in the superficial posterior part of the lung.
Collapse
Affiliation(s)
- Florian Raes
- PHENOMIN-TAAM-UPS44, CIPA (Centre d’Imagerie du Petit Animal), CNRS Orléans, France
- * E-mail:
| | - Julien Sobilo
- PHENOMIN-TAAM-UPS44, CIPA (Centre d’Imagerie du Petit Animal), CNRS Orléans, France
| | - Marilyne Le Mée
- PHENOMIN-TAAM-UPS44, CIPA (Centre d’Imagerie du Petit Animal), CNRS Orléans, France
| | - Stéphanie Rétif
- PHENOMIN-TAAM-UPS44, CIPA (Centre d’Imagerie du Petit Animal), CNRS Orléans, France
| | - Sharuja Natkunarajah
- PHENOMIN-TAAM-UPS44, CIPA (Centre d’Imagerie du Petit Animal), CNRS Orléans, France
| | - Stéphanie Lerondel
- PHENOMIN-TAAM-UPS44, CIPA (Centre d’Imagerie du Petit Animal), CNRS Orléans, France
| | - Alain Le Pape
- PHENOMIN-TAAM-UPS44, CIPA (Centre d’Imagerie du Petit Animal), CNRS Orléans, France
- INSERM U1100, CEPR, University of Tours, France
| |
Collapse
|
18
|
Raes F, Barre T, Jose J, Trochet P, Lerondel S, Pape AL. Abstract 2048: Characterization of tumor hypoxia by photoacoustic imaging and limitations of bioluminescence imaging in a Mia PaCa2-luc orthotopic model of pancreatic carcinoma. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-2048] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Photoacoustic (PA) imaging is a recent promising modality combining advantages of ultrasounds (resolution) and photon imaging (sensitivity), thus providing anatomical and functional data. PA can be implemented by using the natural endogenous contrast agent hemoglobin, providing informations such as the oxygen saturation of hemoglobin (SO2). In the field of oncology, when tumors are growing, the central area becomes hypoxic. This phenomenon does not interfere with tumor growth because cancer cells can switch from aerobic metabolism (using O2) to anaerobic metabolism. Hypoxia is a crucial parameter that needs to be investigated and quantified as it is responsible for radio and chemoresistances. Among tumor cell lines, the MIA PaCa2 cell line (pancreatic adenocarcinoma) appeared quite relevant for a preclinical approach.
The aim of this work was to assess the hypoxic status of tumors in a MIA PaCa-2 Luc+ orthotopic cancer model, and to compare bioluminescent signal and tumor volumes in a longitudinal study.
Methods
The tumor proliferation was monitored by bioluminescence imaging (BLI) and tumor volume with Ultrasound (US). BLI was performed using the IVIS-Lumina II imaging system (PerkinElmer) whereas US and PA with the VEVO LAZR system (VisualSonics). For the experiments, human ductal adenocarcinoma MIA PaCa-2-luc model was orthotopically implanted in nude mice. For the experiment, 7 days after engraftments, tumors were explored both by BLI and US 3 times a week during 12 weeks. Moreover, tumors were investigated by PA imaging so that average values of SO2 were calculated.
Results and Discussion
BLI was selected as it is one of the reference techniques to assess tumor growth in vivo. Overall, our data demonstrated that in our model there was a correlation between BLI and US measurements during the first four weeks of the study. But we observed a significant decrease in BLI signals whereas tumor volumes were continuously increasing. Bioluminescence reaction needs ATP and O2 to occur. In hypoxic situations, light emission becomes not proportional to tumor volume, due to the dependence of luciferin-luciferase reaction towards the metabolism. It appeared that BLI was no longer relevant in the study of advanced stages of MiaPaCa-2 tumors. PA imaging confirmed that there was hypoxia into tumors, approximately since the 5th week. So we were able, thanks to this approach, to accurately map the areas of hypoxia within the tumor.
These results confirm that BLI should be used with caution, in particular during an evaluation of a therapeutic drug. The combination of these three methods (BLI, US, PA) should therefore allow to precisely characterize orthotopic tumor models including the control of the appearance or location of a hypoxic state within tumors, while specifying the limits of bioluminescence.
Citation Format: Florian Raes, Thomas Barre, Jithin Jose, Philippe Trochet, Stéphanie Lerondel, Alain Le Pape. Characterization of tumor hypoxia by photoacoustic imaging and limitations of bioluminescence imaging in a Mia PaCa2-luc orthotopic model of pancreatic carcinoma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2048. doi:10.1158/1538-7445.AM2014-2048
Collapse
Affiliation(s)
| | | | - Jithin Jose
- 2FUJIFILM Visualsonics Inc., Amsterdam, Netherlands
| | | | | | - Alain L. Pape
- 3TAAM UPS44, CIPA, CNRS // INSERM U1100/EA6305 CEPR, Orleans // Tours, France
| |
Collapse
|
19
|
Brullé L, Vandamme M, Riès D, Martel E, Robert E, Lerondel S, Trichet V, Richard S, Pouvesle JM, Le Pape A. Effects of a non thermal plasma treatment alone or in combination with gemcitabine in a MIA PaCa2-luc orthotopic pancreatic carcinoma model. PLoS One 2012; 7:e52653. [PMID: 23300736 PMCID: PMC3530450 DOI: 10.1371/journal.pone.0052653] [Citation(s) in RCA: 181] [Impact Index Per Article: 15.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2012] [Accepted: 11/19/2012] [Indexed: 12/01/2022] Open
Abstract
Pancreatic tumors are the gastrointestinal cancer with the worst prognosis in humans and with a survival rate of 5% at 5 years. Nowadays, no chemotherapy has demonstrated efficacy in terms of survival for this cancer. Previous study focused on the development of a new therapy by non thermal plasma showed significant effects on tumor growth for colorectal carcinoma and glioblastoma. To allow targeted treatment, a fibered plasma (Plasma Gun) was developed and its evaluation was performed on an orthotopic mouse model of human pancreatic carcinoma using a MIA PaCa2-luc bioluminescent cell line. The aim of this study was to characterize this pancreatic carcinoma model and to determine the effects of Plasma Gun alone or in combination with gemcitabine. During a 36 days period, quantitative BLI could be used to follow the tumor progression and we demonstrated that plasma gun induced an inhibition of MIA PaCa2-luc cells proliferation in vitro and in vivo and that this effect could be improved by association with gemcitabine possibly thanks to its radiosensitizing properties.
Collapse
Affiliation(s)
- Laura Brullé
- Centre d'Imagerie du Petit Animal-CIPA TAAM, UPS44 CNRS, Orléans, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Legigan T, Clarhaut J, Tranoy-Opalinski I, Monvoisin A, Renoux B, Thomas M, Le Pape A, Lerondel S, Papot S. Inside Cover: The First Generation of β-Galactosidase-Responsive Prodrugs Designed for the Selective Treatment of Solid Tumors in Prodrug Monotherapy (Angew. Chem. Int. Ed. 46/2012). Angew Chem Int Ed Engl 2012. [DOI: 10.1002/anie.201207805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
21
|
Legigan T, Clarhaut J, Tranoy-Opalinski I, Monvoisin A, Renoux B, Thomas M, Le Pape A, Lerondel S, Papot S. Innentitelbild: The First Generation of β-Galactosidase-Responsive Prodrugs Designed for the Selective Treatment of Solid Tumors in Prodrug Monotherapy (Angew. Chem. 46/2012). Angew Chem Int Ed Engl 2012. [DOI: 10.1002/ange.201207805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
22
|
Legigan T, Clarhaut J, Tranoy-Opalinski I, Monvoisin A, Renoux B, Thomas M, Le Pape A, Lerondel S, Papot S. The First Generation of β-Galactosidase-Responsive Prodrugs Designed for the Selective Treatment of Solid Tumors in Prodrug Monotherapy. Angew Chem Int Ed Engl 2012; 51:11606-10. [DOI: 10.1002/anie.201204935] [Citation(s) in RCA: 78] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2012] [Revised: 07/16/2012] [Indexed: 11/06/2022]
|
23
|
Lavergne M, Iochmann S, Bléchet C, Lerondel S, Heuze-Vourc'h N, Gaud G, Lemarie E, LePape A, Guyetant S, Reverdiau P. 805 Monitoring of Human Lung Tumour Progression Inhibited by TFPI-2 Using Imaging in Mice Orthotopic Models. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71438-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
24
|
Debray D, Rainteau D, Barbu V, Rouahi M, Mourabit HE, Lerondel S, Rey C, Humbert L, Wendum D, Cottart CH, Dawson P, Chignard N, Housset C. Defects in gallbladder emptying and bile Acid homeostasis in mice with cystic fibrosis transmembrane conductance regulator deficiencies. Gastroenterology 2012; 142:1581-91.e6. [PMID: 22370478 PMCID: PMC3579557 DOI: 10.1053/j.gastro.2012.02.033] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/04/2011] [Revised: 02/06/2012] [Accepted: 02/15/2012] [Indexed: 12/13/2022]
Abstract
BACKGROUND & AIMS Patients with cystic fibrosis (CF) have poorly defined defects in biliary function. We evaluated the effects of cystic fibrosis transmembrane conductance regulator (CFTR) deficiency on the enterohepatic disposition of bile acids (BAs). METHODS Bile secretion and BA homeostasis were investigated in Cftr(tm1Unc) (Cftr-/-) and CftrΔF508 (ΔF508) mice. RESULTS Cftr-/- and ΔF508 mice did not grow to normal size, but did not have liver abnormalities. The gallbladders of Cftr-/- mice were enlarged and had defects in emptying, based on (99m)technetium-mebrofenin scintigraphy or post-prandial variations in gallbladder volume; gallbladder contraction in response to cholecystokinin-8 was normal. Cftr-/- mice had abnormal gallbladder bile and duodenal acidity, and overexpressed the vasoactive intestinal peptide-a myorelaxant factor for the gallbladder. The BA pool was larger in Cftr-/- than wild-type mice, although there were no differences in fecal loss of BAs. Amounts of secondary BAs in portal blood, liver, and bile of Cftr-/- mice were much lower than normal. Expression of genes that are induced by BAs, including fibroblast growth factor-15 and BA transporters, was lower in the ileum but higher in the gallbladders of Cftr-/- mice, compared with wild-type mice, whereas enzymes that synthesize BA were down-regulated in livers of Cftr-/- mice. This indicates that BAs underwent a cholecystohepatic shunt, which was confirmed using cholyl-(Ne-NBD)-lysine as a tracer. In Cftr-/- mice, cholecystectomy reversed most changes in gene expression and partially restored circulating levels of secondary BAs. The ΔF508 mice overexpressed vasoactive intestinal peptide and had defects in gallbladder emptying and in levels of secondary BAs, but these features were less severe than in Cftr-/- mice. CONCLUSIONS Cftr-/- and CftrΔF508 mice have defects in gallbladder emptying that disrupt enterohepatic circulation of BAs. These defects create a shunt pathway that restricts the amount of toxic secondary BAs that enter the liver.
Collapse
Affiliation(s)
- Dominique Debray
- UPMC Univ Paris 06 and INSERM, UMR_S 938, CdR Saint-Antoine, Paris, France,AP-HP, Hôpital Necker-Enfants Malades, Hépato-Gastroentérologie Pédiatrique, Paris, France
| | - Dominique Rainteau
- UPMC Univ Paris 06 and INSERM, ERL U1057/UMR 7203, Paris, France,AP-HP, Hôpital Saint-Antoine, Biochimie, Hépato-Gastroentérologie & Anatomo-Pathologie, Paris, France
| | - Véronique Barbu
- UPMC Univ Paris 06 and INSERM, UMR_S 938, CdR Saint-Antoine, Paris, France,AP-HP, Hôpital Saint-Antoine, Biochimie, Hépato-Gastroentérologie & Anatomo-Pathologie, Paris, France
| | - Myriam Rouahi
- UPMC Univ Paris 06 and INSERM, UMR_S 938, CdR Saint-Antoine, Paris, France
| | | | | | - Colette Rey
- UPMC Univ Paris 06 and INSERM, UMR_S 938, CdR Saint-Antoine, Paris, France
| | - Lydie Humbert
- UPMC Univ Paris 06 and INSERM, ERL U1057/UMR 7203, Paris, France
| | - Dominique Wendum
- UPMC Univ Paris 06 and INSERM, UMR_S 938, CdR Saint-Antoine, Paris, France,AP-HP, Hôpital Saint-Antoine, Biochimie, Hépato-Gastroentérologie & Anatomo-Pathologie, Paris, France
| | - Charles-Henry Cottart
- UPMC Univ Paris 06 and INSERM, UMR_S 938, CdR Saint-Antoine, Paris, France,Université Paris Descartes, EA 4466, Faculté des Sciences Pharmaceutiques et Biologiques, Paris, France
| | - Paul Dawson
- Section on Gastroenterology, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina
| | - Nicolas Chignard
- UPMC Univ Paris 06 and INSERM, UMR_S 938, CdR Saint-Antoine, Paris, France
| | - Chantal Housset
- UPMC Univ Paris 06 and INSERM, UMR_S 938, CdR Saint-Antoine, Paris, France,AP-HP, Hôpital Saint-Antoine, Biochimie, Hépato-Gastroentérologie & Anatomo-Pathologie, Paris, France
| |
Collapse
|
25
|
Gaud G, Iochmann S, Guillon-Munos A, Brillet B, Petiot S, Seigneuret F, Touzé A, Heuzé-Vourc'h N, Courty Y, Lerondel S, Gruel Y, Reverdiau P. TFPI-2 silencing increases tumour progression and promotes metalloproteinase 1 and 3 induction through tumour-stromal cell interactions. J Cell Mol Med 2012; 15:196-208. [PMID: 20015200 PMCID: PMC3822788 DOI: 10.1111/j.1582-4934.2009.00989.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Tissue factor pathway inhibitor-2 (TFPI-2) is a potent inhibitor of plasmin which activates matrix metalloproteinases (MMPs) involved in degradation of the extracellular matrix. Its secretion in the tumour microenvironment makes TFPI-2 a potential inhibitor of tumour invasion and metastasis. As demonstrated in aggressive cancers, TFPI-2 is frequently down-regulated in cancer cells, but the mechanisms involved in the inhibition of tumour progression remained unclear. We showed in this study that stable TFPI-2 down-regulation in the National Cancer Institute (NCI)-H460 non-small cell lung cancer cell line using specific micro interfering micro-interfering RNA promoted tumour progression in a nude mice orthotopic model that resulted in an increase in cell invasion. Moreover, TFPI-2 down-regulation enhanced cell adhesion to collagen IV and laminin via an increase in α1 integrin on cell surface, and increased MMP expression (mainly MMP-1 and -3) contributing to cancer cell invasion through basement membrane components. This study also reveals for the first time that pulmonary fibroblasts incubated with conditioned media from TFPI-2 silencing cancer cells exhibited increased expression of MMPs, particularly MMP-1, -3 and -7, that are likely involved in lung cancer cell invasion through the surrounding stromal tissue, thus enhancing formation of metastases.
Collapse
Affiliation(s)
- Guillaume Gaud
- Inserm, U618, Université François Rabelais, Tours, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
|
27
|
Iochmann S, Lerondel S, Bléchet C, Lavergne M, Pesnel S, Sobilo J, Heuzé-Vourc'h N, Le Pape A, Reverdiau P. Monitoring of tumour progression using bioluminescence imaging and computed tomography scanning in a nude mouse orthotopic model of human small cell lung cancer. Lung Cancer 2012; 77:70-6. [PMID: 22321610 DOI: 10.1016/j.lungcan.2012.01.009] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2011] [Revised: 12/23/2011] [Accepted: 01/15/2012] [Indexed: 11/18/2022]
Abstract
Human small cell lung carcinoma (SCLC) is the most aggressive type of lung cancer but no clinically relevant animal model has been developed to date. Such a model would be valuable to study the molecular aspects of tumour progression and to test the effectiveness of new treatment agents. We generated a reproducible and reliable nude mouse orthotopic model of human SCLC with NCI-H209 tumour cells genetically modified to express firefly luciferase. Cells were analysed for long-term stability of bioluminescence and a clone was passaged twice subcutaneously to enhance tumorigenicity. Cells resuspended in Matrigel and/or EDTA RPMI medium containing a (99m)Tc-labelled tin colloid used as tracer were implanted intrabronchially with a catheter inserted into the trachea and positioned in the main bronchus using X-ray-guided imaging. Deposition of cells into the lung was then assessed by scintigraphy. The growth of the primary tumour was sensitively and non-invasively followed by bioluminescence imaging that allowed real-time monitoring of tumour progression in the same animals over a 2-12-week period. Additional 3D bioluminescence imaging and computed tomography scanning were used to document tumour location and measurements that were confirmed by histological analyses. In conclusion, this original nude mouse orthotopic model resembles various stages of human small cell lung cancer, and therefore could be used to evaluate new treatment strategies.
Collapse
Affiliation(s)
- Sophie Iochmann
- Inserm U618, Université François Rabelais, IFR 135, F-37032 Tours, France
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Pesnel S, Pillon A, Créancier L, Lerondel S, Le Pape A, Recher C, Demur C, Guilbaud N, Kruczynski A. Optical imaging of disseminated leukemia models in mice with near-infrared probe conjugated to a monoclonal antibody. PLoS One 2012; 7:e30690. [PMID: 22303450 PMCID: PMC3267751 DOI: 10.1371/journal.pone.0030690] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2011] [Accepted: 12/22/2011] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND The assessment of anticancer agents to treat leukemia needs to have animal models closer to the human pathology such as implantation in immunodeficient mice of leukemic cells from patient samples. A sensitive and early detection of tumor cells in these orthotopic models is a prerequisite for monitoring engraftment of leukemic cells and their dissemination in mice. Therefore, we developed a fluorescent antibody based strategy to detect leukemic foci in mice bearing patient-derived leukemic cells using fluorescence reflectance imaging (FRI) to determine when to start treatments with novel antitumor agents. METHODS Two mAbs against the CD44 human myeloid marker or the CD45 human leukocyte marker were labeled with Alexa Fluor 750 and administered to leukemia-bearing mice after having verified the immunoreactivity in vitro. Bioluminescent leukemic cells (HL60-Luc) were used to compare the colocalization of the fluorescent mAb with these cells. The impact of the labeled antibodies on disease progression was further determined. Finally, the fluorescent hCD45 mAb was tested in mice engrafted with human leukemic cells. RESULTS The probe labeling did not modify the immunoreactivity of the mAbs. There was a satisfactory correlation between bioluminescence imaging (BLI) and FRI and low doses of mAb were sufficient to detect leukemic foci. However, anti-hCD44 mAb had a strong impact on the tumor proliferation contrary to anti-hCD45 mAb. The use of anti-hCD45 mAb allowed the detection of leukemic patient cells engrafted onto NOD/SCID mice. CONCLUSIONS A mAb labeled with a near infrared fluorochrome is useful to detect leukemic foci in disseminated models provided that its potential impact on tumor proliferation has been thoroughly documented.
Collapse
MESH Headings
- Animals
- Antibodies, Monoclonal/administration & dosage
- Antibodies, Monoclonal/immunology
- Cell Line, Tumor
- Cell Transformation, Neoplastic/pathology
- Disease Models, Animal
- Flow Cytometry
- Fluorescent Dyes/metabolism
- Humans
- Imaging, Three-Dimensional/methods
- Injections, Intravenous
- Leukemia/diagnosis
- Leukemia/pathology
- Leukemia, Myeloid, Acute/pathology
- Leukocyte Common Antigens/metabolism
- Longevity
- Luminescent Measurements
- Mice
- Mice, SCID
- Reproducibility of Results
- Spectroscopy, Near-Infrared/methods
Collapse
Affiliation(s)
- Sabrina Pesnel
- Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Robert E, Vandamme M, Sobilo J, Sarron V, Ries D, Dozias S, Brulle L, Lerondel S, Le Pape A, Pouvesle JM. First Achievements and Opportunities for Cancer Treatment Using Non-thermal Plasma. Plasma for Bio-Decontamination, Medicine and Food Security 2012. [DOI: 10.1007/978-94-007-2852-3_29] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
|
30
|
Pesnel S, Akkoul S, Ledée R, Leconge R, Pillon A, Kruczynski A, Harba R, Lerondel S, Le Pape A. Use of an image restoration process to improve spatial resolution in bioluminescence imaging. Mol Imaging 2011; 10:446-452. [PMID: 22201535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023] Open
Abstract
To improve spatial resolution in in vivo bioluminescence imaging, a photon scattering correction, image restoration method was tested. The chosen algorithm was tested on in vivo bioluminescent images acquired on three representative tumor models: subcutaneous, pulmonary, and disseminated peritoneal. Tumor size was chosen as a quantitative criterion, such that the tumor reference measurements (determined photographically or by computed tomography) were compared to those derived from bioluminescent images, before and after restoration. This technique allowed a significant reduction to be achieved in the relative error between reference measurements and dimensions derived from bioluminescent images. In addition, improved delineation of the tumor foci was achieved. The restoration method allows spatial resolution in bioluminescence imaging to be improved, with interesting perspectives in terms of staging and quantitation in experimental oncology.
Collapse
|
31
|
Pesnel S, Akkoul S, Ledée R, Leconge R, Pillon A, Kruczynski A, Harba R, Lerondel S, Le Pape A. Use of an Image Restoration Process to Improve Spatial Resolution in Bioluminescence Imaging. Mol Imaging 2011. [DOI: 10.2310/7290.2011.00012] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
To improve spatial resolution in in vivo bioluminescence imaging, a photon scattering correction, image restoration method was tested. The chosen algorithm was tested on in vivo bioluminescent images acquired on three representative tumor models: subcutaneous, pulmonary, and disseminated peritoneal. Tumor size was chosen as a quantitative criterion, such that the tumor reference measurements (determined photographically or by computed tomography) were compared to those derived from bioluminescent images, before and after restoration. This technique allowed a significant reduction to be achieved in the relative error between reference measurements and dimensions derived from bioluminescent images. In addition, improved delineation of the tumor foci was achieved. The restoration method allows spatial resolution in bioluminescence imaging to be improved, with interesting perspectives in terms of staging and quantitation in experimental oncology.
Collapse
Affiliation(s)
- Sabrina Pesnel
- From UPS n°44 TAAM – CIPA, CNRS, Orléans, France; Institut PRISME, Université d'Orléans, Orléans, France; Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, France; and INSERM U618, UniversitAeA de Tours, Tours, France
| | - Smaïl Akkoul
- From UPS n°44 TAAM – CIPA, CNRS, Orléans, France; Institut PRISME, Université d'Orléans, Orléans, France; Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, France; and INSERM U618, UniversitAeA de Tours, Tours, France
| | - Roger Ledée
- From UPS n°44 TAAM – CIPA, CNRS, Orléans, France; Institut PRISME, Université d'Orléans, Orléans, France; Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, France; and INSERM U618, UniversitAeA de Tours, Tours, France
| | - Rémy Leconge
- From UPS n°44 TAAM – CIPA, CNRS, Orléans, France; Institut PRISME, Université d'Orléans, Orléans, France; Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, France; and INSERM U618, UniversitAeA de Tours, Tours, France
| | - Arnaud Pillon
- From UPS n°44 TAAM – CIPA, CNRS, Orléans, France; Institut PRISME, Université d'Orléans, Orléans, France; Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, France; and INSERM U618, UniversitAeA de Tours, Tours, France
| | - Anna Kruczynski
- From UPS n°44 TAAM – CIPA, CNRS, Orléans, France; Institut PRISME, Université d'Orléans, Orléans, France; Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, France; and INSERM U618, UniversitAeA de Tours, Tours, France
| | - Rachid Harba
- From UPS n°44 TAAM – CIPA, CNRS, Orléans, France; Institut PRISME, Université d'Orléans, Orléans, France; Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, France; and INSERM U618, UniversitAeA de Tours, Tours, France
| | - Stéphanie Lerondel
- From UPS n°44 TAAM – CIPA, CNRS, Orléans, France; Institut PRISME, Université d'Orléans, Orléans, France; Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, France; and INSERM U618, UniversitAeA de Tours, Tours, France
| | - Alain Le Pape
- From UPS n°44 TAAM – CIPA, CNRS, Orléans, France; Institut PRISME, Université d'Orléans, Orléans, France; Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, France; and INSERM U618, UniversitAeA de Tours, Tours, France
| |
Collapse
|
32
|
Vandamme M, Robert E, Lerondel S, Sarron V, Ries D, Dozias S, Sobilo J, Gosset D, Kieda C, Legrain B, Pouvesle JM, Pape AL. ROS implication in a new antitumor strategy based on non-thermal plasma. Int J Cancer 2011; 130:2185-94. [PMID: 21702038 DOI: 10.1002/ijc.26252] [Citation(s) in RCA: 274] [Impact Index Per Article: 21.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2011] [Accepted: 05/30/2011] [Indexed: 12/14/2022]
Abstract
Non-thermal plasma (NTP) is generated by ionizing neutral gas molecules/atoms leading to a highly reactive gas at ambient temperature containing excited molecules, reactive species and generating transient electric fields. Given its potential to interact with tissue or cells without a significant temperature increase, NTP appears as a promising approach for the treatment of various diseases including cancer. The aim of our study was to evaluate the interest of NTP both in vitro and in vivo. To this end, we evaluated the antitumor activity of NTP in vitro on two human cancer cell lines (glioblastoma U87MG and colorectal carcinoma HCT-116). Our data showed that NTP generated a large amount of reactive oxygen species (ROS), leading to the formation of DNA damages. This resulted in a multiphase cell cycle arrest and a subsequent apoptosis induction. In addition, in vivo experiments on U87MG bearing mice showed that NTP induced a reduction of bioluminescence and tumor volume as compared to nontreated mice. An induction of apoptosis was also observed together with an accumulation of cells in S phase of the cell cycle suggesting an arrest of tumor proliferation. In conclusion, we demonstrated here that the potential of NTP to generate ROS renders this strategy particularly promising in the context of tumor treatment.
Collapse
|
33
|
Le Pape A, Réveillon G, Lerondel S. Imaging modalities and their usefulness in non-clinical safety assessment. Toxicol Lett 2011. [DOI: 10.1016/j.toxlet.2011.05.098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
34
|
Pesnel S, Guminski Y, Pillon A, Lerondel S, Imbert T, Guilbaud N, Kruczynski A, Bailly C, Le Pape A. 99mTc-HYNIC-spermine for imaging polyamine transport system-positive tumours: preclinical evaluation. Eur J Nucl Med Mol Imaging 2011; 38:1832-41. [PMID: 21660624 DOI: 10.1007/s00259-011-1857-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2011] [Accepted: 05/26/2011] [Indexed: 11/28/2022]
Abstract
PURPOSE F14512 exploiting the polyamine transport system (PTS) for tumour cell delivery has been described as a potent antitumour agent. The optimal use of this compound will require a probe to identify tumour cells expressing a highly active PTS that might be more sensitive to the treatment. The aim of this study was to design and characterize a scintigraphic probe to evaluate its uptake in cancer cells expressing the PTS. METHODS Three polyamines coupled to a hydrazinonicotinamide (HYNIC) moiety were synthesized and labelled with 99mTc. Their radiochemical purity was determined by HPLC. The plasma stability of the 99mTc-HYNIC-spermine probe and its capacity to accumulate into PTS-active cells were also evaluated. In vitro internalization was tested using murine melanoma B16/F10 cells and human lung carcinoma A549 cells. Biodistribution was determined in healthy mice and tumour uptake was studied in B16/F10 tumour-bearing mice. A HL-60-Luc human leukaemia model was used to confront single photon emission computed tomography (SPECT) images obtained with the 99mTc-labelled probe with those obtained by bioluminescence. RESULTS The 99mTc-HYNIC-spermine probe was selected for its capacity to accumulate into PTS-active cells and its stability in plasma. In vitro studies demonstrated that the probe was internalized in the cells via the PTS. In vivo measurements indicated a tumour to muscle scintigraphic ratio of 7.9±2.8. The combined bioluminescence and scintigraphic analyses with the leukaemia model demonstrated that the spermine conjugate accumulates into the tumour cells. CONCLUSION The 99mTc-HYNIC-spermine scintigraphic probe is potentially useful to characterize the PTS activity of tumours. Additional work is needed to determine if this novel conjugate may be useful to analyse the PTS status of patients with solid tumours.
Collapse
Affiliation(s)
- Sabrina Pesnel
- Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, France,
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Debray D, Rainteau D, Lerondel S, Rey C, Humbert L, Barbu V, Wolf C, Cottart C, Housset C. Gallbladder dysfunction contributes to impaired bile salt homeostasis in cystic fibrosis. J Cyst Fibros 2009. [DOI: 10.1016/s1569-1993(09)60307-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
36
|
Bridot JL, Dayde D, Rivière C, Mandon C, Billotey C, Lerondel S, Sabattier R, Cartron G, Le Pape A, Blondiaux G, Janier M, Perriat P, Roux S, Tillement O. Hybrid gadolinium oxide nanoparticles combining imaging and therapy. ACTA ACUST UNITED AC 2009. [DOI: 10.1039/b815836c] [Citation(s) in RCA: 61] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
37
|
Iochmann S, Lerondel S, Blechet C, Pesnel S, Heuze-Vourc’h N, Gruel Y, Le Pape A, Reverdiau P. Monitoring of tumor progression using bioluminescence imaging in a nude mice orthotopic model of human small cell lung cancer. Rev Mal Respir 2008. [DOI: 10.1016/s0761-8425(08)75014-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
38
|
Iochmann S, Lerondel S, Bléchet C, Pesnel S, Heuzé-Vourc'h N, Gruel Y, Le Pape A, Reverdiau P. Monitoring of tumor progression using bioluminescence imaging in a nude mice orthotopic model of human small cell lung cancer. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)71447-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
39
|
Bridot JL, Dayde D, Faure AC, Laurent S, Rivière C, Billotey C, Hiba B, Janier M, Josserand V, Coll JL, Vander Elst L, Muller R, Sabattier R, Lerondel S, Lepape A, Perriat P, Roux S, Tillement O. CMR 2007: 7.07: Hybrid gadolinium oxide nanoparticles: contrast agents combining diagnosis and therapy. Contrast Media Mol Imaging 2008. [DOI: 10.1002/cmmi.192] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
40
|
Gagnadoux F, Pape AL, Lemarié E, Lerondel S, Valo I, Leblond V, Racineux JL, Urban T. Aerosol delivery of chemotherapy in an orthotopic model of lung cancer. Eur Respir J 2006; 26:657-61. [PMID: 16204597 DOI: 10.1183/09031936.05.00017305] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The aim of this study was to evaluate the effect on tumour growth of gemcitabine delivered by aerosol in an orthotopic model of lung carcinoma. Large cell carcinoma (NCI-H460) cells were implanted intrabronchially in 24 male BALB/c nude mice on day (d) 0. Aerosols were delivered once a week from d1 to d29 using an endotracheal sprayer. Altogether, 16 animals received gemcitabine at 8 (n=8) and 12 mg.kg-1 (n=8), and eight received a vehicle aerosol. Animals were sacrificed on d36 for histological examination. All animals in the vehicle group developed a large infiltrating carcinoma. Comparatively, four of 13 (31%) animals treated with gemcitabine had no visible tumour and nine of 13 (69%) had a smaller carcinoma with a mean+/-sem largest tumour diameter of 2.05+/-0.7 versus 5+/-0.3 mm in the vehicle group. Gemcitabine was well tolerated at 8 mg.kg-1. At 12 mg.kg-1, three cases of fatal pulmonary oedema were observed, prompting a dose reduction to 8 mg.kg-1 in the remaining animals. A dose effect was observed, with more marked tumour growth inhibition in the animals treated at 12 mg.kg-1 on d1 and d8. In conclusion, in this study, an animal model of aerosolised chemotherapy in lung cancer was developed and demonstrated inhibition of orthotopic tumour growth by aerosol delivery of gemcitabine.
Collapse
Affiliation(s)
- F Gagnadoux
- Groupe de pneumologie, INSERM, U618, Faculté de Médecine, Tours, France.
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Gagnadoux F, Le Pape A, Urban T, Hureaux J, Vecellio L, Valo I, Lerondel S, Leblond V, Diot P, Racineux J, Lemarie E. 041 Étude pré-clinique d’une administration de chimiothérapie en aerosol dans le carcinome broncho-pulmonaire. Rev Mal Respir 2005. [DOI: 10.1016/s0761-8425(05)92453-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
42
|
Lerondel S, Vecellio None L, Faure L, Sizaret PY, Sene C, Pavirani A, Diot P, Le Pape A. Gene therapy for cystic fibrosis with aerosolized adenovirus-CFTR: characterization of the aerosol and scintigraphic determination of lung deposition in baboons. J Aerosol Med 2001; 14:95-105. [PMID: 11495490 DOI: 10.1089/08942680152007945] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
For cystic fibrosis (CF) gene therapy using an aerosolized adenovirus expressing the CFTR gene, optimization of the inhalation conditions is a prerequisite to obtain sufficient amount of CFTR protein expression in the target areas of the respiratory tract. For such a purpose, in vivo radioisotopic imaging of the radiolabeled virus is a unique strategy for a quantitative assessment of the actual deposition. In the present study, an adenovirus CFTR (AdCFTR) was labeled with 99m Technetium gamma emitting isotope in such conditions that its bioactivity was preserved. The 99mTc-AdCFTR aerosol was characterized using both laser diffraction and cascade impaction for sizing with further determination of nebulized and inhalable fractions. After administration to baboons, scintigraphic quantitation of the regional lung distribution was performed and the actual dose deposited in the target area was estimated and expressed as an equivalent viral titer. Since a virus scintigraphy is not realistic in a hospital setting, we have developed an approach using 99mTc-DTPA (diethylene triamino pentaacetic acid) that could be used to predict the virus deposition. Indeed, similarities observed between 99mTc-DTPA and 99mTc-adenovirus aerosol imaging patterns validates the use of the 99mTc-DTPA scintigraphy that we propose as a pretherapeutic test for each patient prior to gene transfer.
Collapse
Affiliation(s)
- S Lerondel
- INSERM EMI-U 0010, Faculté de Médecine, Tours, France.
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Lerondel S, Le Pape A, Sené C, Faure L, Bernard S, Diot P, Nicolis E, Mehtali M, Lusky M, Cabrini G, Pavirani A. Radioisotopic imaging allows optimization of adenovirus lung deposition for cystic fibrosis gene therapy. Hum Gene Ther 2001; 12:1-11. [PMID: 11177537 DOI: 10.1089/104303401450915] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Cystic fibrosis is a common, heriditary disease resulting from mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Airway transfer of the CFTR gene is a potential strategy to treat or prevent the lung pathology that is the main cause of morbidity and mortality. Among the vectors used for gene therapy, adenoviruses have shown their ability to transfer the CFTR gene to respiratory epithelial cells, using either instillation or nebulization. Our objective was to characterize the lung deposition of aerosolized adenovirus by quantitative radioisotopic imaging, the only noninvasive technique allowing in vivo quantitation of inhaled drugs. We first labeled an adenovirus expressing human CFTR with the gamma-emitting radioisotope, technetium 99m (99mTc), and determined the best labeling conditions to allow preservation of virus bioactivity. We then administered the radioaerosol to baboons, determined lung regional deposition of 99mTc-labeled adenovirus, and compared the expression of CFTR transcripts 3 and 21 days after inhalation. The expression of vector-encoded mRNA ranged from 4 to 22% with respect to the endogenous CFTR mRNA depending on the lung segments. Moreover, we have developed a model using 99mTc-DTPA (diethylenetriamine pentaacetic acid), which can be used, as an alternative to adenovirus, to determine the profile of lung deposition of the vector. This study demonstrates that scintigraphy is a useful technique to achieve optimization of gene administration to the airways.
Collapse
Affiliation(s)
- S Lerondel
- INSERM, EMI U00-10 Faculté de Médecine, 37032 Tours, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|